The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAssertio Holdings and Garda Therapeutics have mutually agreed to extend the commencement deadline for their previously announced tender offer to May 4, 2026. Under the terms of the definitive agreement, Garda is set to acquire all outstanding shares of Assertio at a price of $18.00 per share. This extension provides both parties with additional time to initiate the acquisition process as outlined in the existing merger framework. While the timeline has shifted significantly, the acquisition price remains fixed at the previously agreed-upon premium. This procedural update reflects ongoing coordination between the two pharmaceutical entities to ensure a smooth transition. Market participants are viewing this delay as a neutral administrative adjustment to the M&A timeline. No further changes to the structural terms of the deal were disclosed in the latest filing.